```
=> d
L1 HAS NO ANSWERS
L1                STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 12:24:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -   1316 TO ITERATE

 76.0% PROCESSED    1000 ITERATIONS                                1 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:        24144 TO    28496
PROJECTED ANSWERS:               1 TO       94

L2             1 SEA SSS SAM L1

=> d
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301222-78-6 REGISTRY
CN 1H-Indole-6-acetamide,
N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl
]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-3-[[[5-
[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-
yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]- (9CI) (CA
INDEX NAME)
FS 3D CONCORD
MF C45 H57 N13 O6
CI COM
SR CA

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L.

1. East class subclass

L5 ANSWER 1 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301222-84-4 REGISTRY
CN 1H-Indole-3-carboxamide,
N-{5-[[[5-[[[3-(dimethylamino)propyl]amino]carbon

yl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-6-[3-[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxo-1-propenyl]-(9CI)
(CA INDEX NAME)
FS 3D CONCORD
MF C46 H57 N13 O6
CI COM
SR CA

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ED Entered STN: 03 Nov 2000

L5 ANSWER 2 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301222-82-2 REGISTRY
CN 1H-Indole-6-propanamide,
N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbon
yl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-3-

[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C46 H59 N13 O6
CI COM
SR CA

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ED Entered STN: 03 Nov 2000

L5 ANSWER 3 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301222-80-0 REGISTRY
CN 1H-Indole-3,6-dicarboxamide, N,N'-bis[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C44 H55 N13 O6
CI COM
SR CA

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ED Entered STN: 03 Nov 2000

L5 ANSWER 4 OF 4 REGISTRY COPYRIGHT 2004 ACS on STN
RN 301222-78-6 REGISTRY
CN 1H-Indole-6-acetamide,
N-{5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl

]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)
FS 3D CONCORD
MF C45 H57 N13 O6
CI COM
SR CA

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ED Entered STN: 03 Nov 2000

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2004:293388 CAPLUS
DOCUMENT NUMBER: 140:303682
TITLE: Preparation of N-heterocyclylindole-3-carboxamides as glucokinase activators
INVENTOR(S): Corbett, Wendy Lea
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 28 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004067939	A1	20040408	US 2003-674481	20030930
WO 2004031179	A1	20040415	WO 2003-EP10776	20030926

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-415737P P 20021003
GI



AB N-(2-thiazolyl), N-(1,3,4-thiadiazol-2-yl), or N-(2-pyridyl)indole-3-carboxamides [I; R1 = halo, NO2, NH2, cyano, Me, CF3, HO, OMe, CF3O, MeS, methylsulfinyl, MeSO2; R2 = lower C2-5 alkyl, CH2R4; wherein R4 = C3-6 cycloalkyl; R3 = an unsubstituted or monosubstituted five- or six-membered heteroarom. ring connected by a ring carbon atom to the amine group shown, which five- or six-membered heteroarom. ring contains from 1 to 3 heteroatoms selected from sulfur, oxygen or nitrogen, with one heteroatom being nitrogen which is adjacent to the connecting ring carbon atom; said monosubstituted heteroarom. ring being monosubstituted at a position on a ring carbon atom other than adjacent to said connecting carbon atom with a

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
N-(thiazol-2-yl)amide **676477-33-1P**, 6-Chloro-1-cyclopentylmethyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-35-3P**, 6-Chloro-1-cyclohexylmethyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-37-5P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid [1,3,4]thiadiazol-2-ylamide **676477-38-6P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-methylthiazol-2-yl)amide **676477-39-7P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(4-methylthiazol-2-yl)amide **676477-40-0P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-chlorothiazol-2-yl)amide **676477-41-1P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-bromothiazol-2-yl)amide **676477-42-2P**, [2-{[(6-Chloro-1-isopropyl-1H-indol-3-yl)carbonyl]amino}thiazol-4-yl]acetic acid Ethyl Ester **676477-43-3P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(pyridin-2-yl)amide **676477-44-4P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-methylpyridin-2-yl)amide **676477-46-6P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-trifluoromethylpyridin-2-yl)amide **676477-49-9P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-chloropyridin-2-yl)amide **676477-51-3P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(5-bromopyridin-2-yl)amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-heterocyclylindole-3-carboxamides as glucokinase activators for increasing insulin secretion in treatment of type II diabetes.

RN 676476-81-6 CAPLUS
CN 1H-Indole-3-carboxamide, 6-methyl-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676476-85-0 CAPLUS
CN 1H-Indole-3-carboxamide, 1-(1-methylethyl)-N-2-thiazolyl-6-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 676476-89-4 CAPLUS
CN 1H-Indole-3-carboxamide, 1-(1-methylethyl)-6-nitro-N-2-thiazolyl- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
substituent selected from the group consisting of Me, CF3, chloro, bromo, NO2, cyano, (CH2)nOR5, (CH2)nCO2R5, (CH2)nCONHR5, and (CH2)nNHR5; wherein n = 0, 1; R5 = H, lower alkyl] or pharmaceutically acceptable salts thereof are prepd. These compds. are glucokinase activators which increase the flux of glucose metab. in β-cells and in turn cause increased insulin secretion, and thereby are useful for increasing insulin secretion in the treatment of type II diabetes.
IT **676476-97-4P**, 1-Isopropyl-6-methoxy-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of N-heterocyclylindole-3-carboxamides as glucokinase activators for increasing insulin secretion in treatment of type II diabetes)
RN 676476-97-4 CAPLUS
CN 1H-Indole-3-carboxamide, 6-methoxy-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



IT **676476-81-6P**, 1-Isopropyl-6-methyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676476-85-0P**, 1-Isopropyl-6-trifluoromethyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676476-89-4P**, 1-Isopropyl-6-nitro-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676476-93-0P**, 6-Hydroxy-1-isopropyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676476-98-5P**, 1-Isopropyl-6-methylsulfanyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-02-4P**, 1-Isopropyl-6-methanesulfonyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-03-5P**, 6-Fluoro-1-isopropyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-06-8P**, 6-Bromo-1-isopropyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-09-1P**, 6-Chloro-1-isopropyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-13-7P**, 6-Chloro-1-ethyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-15-9P**, 6-Chloro-1-propyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-18-2P**, 1-Butyl-6-chloro-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-21-7P**, 6-Chloro-1-isobutyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-24-0P**, 6-Chloro-1-pentyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-26-2P**, 6-Chloro-1-(3-methylbutyl)-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-29-5P**, 6-Chloro-1-cyclopropylmethyl-1H-indole-3-carboxylic acid N-(thiazol-2-yl)amide **676477-31-9P**, 6-Chloro-1-cyclobutylmethyl-1H-indole-3-carboxylic acid

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676476-93-0 CAPLUS
CN 1H-Indole-3-carboxamide, 6-hydroxy-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676476-98-5 CAPLUS
CN 1H-Indole-3-carboxamide, 1-(1-methylethyl)-6-(methylthio)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-02-4 CAPLUS
CN 1H-Indole-3-carboxamide, 1-(1-methylethyl)-6-(methylsulfonyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-03-5 CAPLUS
CN 1H-Indole-3-carboxamide, 6-fluoro-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676477-06-8 CAPLUS
CN 1H-Indole-3-carboxamide, 6-bromo-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-09-1 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-13-7 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-ethyl-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-15-9 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-propyl-N-2-thiazolyl- (9CI) (CA INDEX

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
NAME)



RN 676477-18-2 CAPLUS
CN 1H-Indole-3-carboxamide, 1-butyl-6-chloro-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-21-7 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(2-methylpropyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-24-0 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-pentyl-N-2-thiazolyl- (9CI) (CA INDEX
NAME)



L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RN 676477-26-2 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(3-methylbutyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-29-5 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(cyclopropylmethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-31-9 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(cyclobutylmethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-33-1 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(cyclopentylmethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676477-35-3 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(cyclohexylmethyl)-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 676477-37-5 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-1,3,4-thiadiazol-2-yl- (9CI) (CA INDEX NAME)



RN 676477-38-6 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-(5-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676477-39-7 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-(4-methyl-2-thiazolyl)- (9CI) (CA INDEX NAME)



RN 676477-40-0 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-N-(5-chloro-2-thiazolyl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 676477-41-1 CAPLUS
CN 1H-Indole-3-carboxamide, N-(5-bromo-2-thiazolyl)-6-chloro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)

L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

RN 676477-46-6 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-[5-(trifluoromethyl)-2-pyridinyl]- (9CI) (CA INDEX NAME)



RN 676477-49-9 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-N-(5-chloro-2-pyridinyl)-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 676477-51-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-(5-bromo-2-pyridinyl)-6-chloro-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



L6 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)



RN 676477-42-2 CAPLUS
CN 4-Thiazoleacetic acid, 2-[[[6-chloro-1-(1-methylethyl)-1H-indol-3-yl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 676477-43-3 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 676477-44-4 CAPLUS
CN 1H-Indole-3-carboxamide, 6-chloro-1-(1-methylethyl)-N-(5-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)



2

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:575058 CAPLUS
DOCUMENT NUMBER: 137:140515
TITLE: Preparation of thiazole derivatives exhibiting thrombopoietin receptor agonism
INVENTOR(S): Takemoto, Hiroshi; Takayama, Masami; Yoshida, Yutaka
PATENT ASSIGNEE(S): Shionogi & Co., Ltd., Japan
SOURCE: PCT Int. Appl., 121 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002059099	A1	20020801	WO 2002-JP546	20020125

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1361220	A1	20031112	EP 2002-716382	20020125

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

US 2004082626	A1	20040429	US 2003-470002	20030725

PRIORITY APPLN. INFO.:
JP 2001-17779 A 20010126
JP 2001-223414 A 20010724
WO 2002-JP546 W 20020125

OTHER SOURCE(S): MARPAT 137:140515
GI



I

AB Title compds. [X1-Y1-Z1; X1 = aryl, optionally substituted heteroaryl; Y1 = NRACO(CH2)0-2; RA = hydrogen, etc.; Z1 = two-fused optionally substituted carbon rings and optionally substituted heterocyclesring , which are either the same or different] are prepared and are having a thrombopoietin (TPO) receptor agonism. Title compds., pharmaceutically acceptable salts thereof or solvates of the same are the active ingredient in prodrugs thereof. Thus, the title compound I was prepared from 3,4-dichloroacetylbenzene, thiourea, and 1,2,,3,4-tetrahydronaphthalene-2-carboxylic acid via cyclization, carbonylation, and amination. The title compound I was in vitro tested for TPO receptor responsiveness with ED50(μM) = 0.040.

IT **444572-53-6P**

L6 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of thiazole derivs. exhibiting thrombopoietin receptor agonism)
RN 444572-53-6 CAPLUS
CN 1H-Indole-6-carboxylic acid, 3-[[[4-(3,4-dichlorophenyl)-2-thiazolyl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 64 THERE ARE 64 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

3

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2000:586054 CAPLUS
DOCUMENT NUMBER: 133:296344
TITLE: Synthesis of novel DNA binding agents: Indole-containing analogs of bis-netropsin
AUTHOR(S): Khalaf, Abedawn I.; Pitt, Andrew R.; Scobie, Martin; Suckling, Colin J.; Urwin, John; Waigh, Roger D.; Fishleigh, Robert V.; Young, Stephen C.
CORPORATE SOURCE: Department of Pure and Applied Chemistry, University of Strathclyde, Glasgow, UK
SOURCE: Journal of Chemical Research, Synopses (2000), (9), 264-265
CODEN: JRPSDC; ISSN: 0308-2342
PUBLISHER: Science Reviews Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Mol. modeling studies showed that indole dicarboxylic acids are potential linkers for the synthesis of bisnetropsin analogs with a good fit to the minor groove of DNA. To test this hypothesis, 2-carboxyindole-6-acetic acid, indole-2,6-dicarboxylic acid, 6-(2-carboxyethyl)indole-2-carboxylic acid, and 6-(2-carboxy-1-ethenyl)indole-2-carboxylic acid were prepared and coupled to 3-[1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido]dimethylaminopropane. Similarly, indole-2,5-dicarboxylic acid was prepared and coupled to 3-[1-methyl-4-(1-methyl-4-aminopyrrole-2-carboxamido)pyrrole-2-carboxamido]propionamidine hydrochloride. Some derivs. showed especially strong binding at AT rich regions as shown by footprinting studies.
IT **301222-79-7P 301222-83-3P 301222-85-5P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(indole-containing analogs of bis-netropsin as DNA binding agents)
RN 301222-79-7 CAPLUS
CN 1H-Indole-6-acetamide, N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301222-78-6
CMF C45 H57 N13 O6

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 301222-83-3 CAPLUS
CN 1H-Indole-6-propanamide, N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301222-82-2
CMF C46 H59 N13 O6

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 301222-85-5 CAPLUS
CN 1H-Indole-3-carboxamide, N-[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-6-[3-[[[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]-3-oxo-1-propenyl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301222-84-4
CMF C46 H57 N13 O6

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT **301222-81-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(indole-containing analogs of bis-netropsin as DNA binding agents)
RN 301222-81-1 CAPLUS
CN 1H-Indole-3,6-dicarboxamide, N,N'-bis[5-[[[5-[[[3-(dimethylamino)propyl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]amino]carbonyl]-1-methyl-1H-pyrrol-3-yl]-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 301222-80-0
CMF C44 H55 N13 O6

L6 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN (Continued)

PAGE 1-A



PAGE 1-B



CM 2

CRN 76-05-1
CMF C2 H F3 O2

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	15.58	185.75

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.08	-2.08

FILE 'REGISTRY' ENTERED AT 12:28:15 ON 06 MAY 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 MAY 2004 HIGHEST RN 679784-15-7
DICTIONARY FILE UPDATES: 4 MAY 2004 HIGHEST RN 679784-15-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2004

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
http://www.cas.org/ONLINE/DBSS/registryss.html

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d his

```
     (FILE 'HOME' ENTERED AT 12:23:43 ON 06 MAY 2004)

     FILE 'REGISTRY' ENTERED AT 12:23:48 ON 06 MAY 2004
L1              STRUCTURE UPLOADED
L2            1 S L1
L3           40 S L1 FULL
L4           36 S L3 AND CAPLUS/LC
L5            4 S L3 NOT L4

     FILE 'CAPLUS' ENTERED AT 12:26:12 ON 06 MAY 2004
L6            3 S L3

     FILE 'REGISTRY' ENTERED AT 12:28:15 ON 06 MAY 2004

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                0.42     186.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                0.00      -2.08

STN INTERNATIONAL LOGOFF AT 12:28:26 ON 06 MAY 2004
```